Akademiska Hus is investing 160 million SEK in reconstructing Fysiologen into modern offices and laboratories. The reconstruction is planned to begin in February 2022 and ready for occupation, in stages,
Nordic Life Science
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
NLS News
Elicera Therapeutics has announced that Vinnova has granted the company and its project partners 5 million SEK in grants to develop an automated process for CAR T-cell manufacturing. Elicera Therapeutics
The Board of Directors of Oasmia has resolved on a new issue of shares with preferential rights for existing shareholders of approximately SEK 151 million. The purpose of the Rights
Kristin Wannerberger’s career path has taken her from Sweden, to Denmark and now, Switzerland, where she is Director R&D Alliance Management at Ferring. As Head of R&D Alliance Management at
AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of Enhertu for the treatment of adult patients in the US with unresectable or
Targovax has announced that patents no CN108495934 and JP6974350 have been granted by the Chinese and Japanese Patent Offices, respectively. The patents cover the use of ONCOS-102 in combination with
Observe Medical and the shareholders of Biim Ultrasound have announced a definitive agreement whereby Observe Medical will acquire 100% of the shares in Biim Ultrasound. The transaction, which values Biim
AstraZeneca has signed a collaboration agreement with Scorpion Therapeutics to discover, develop and commercialize precision medicines against previously hard-to-target cancer proteins, with the potential to transform oncology treatment. “Unlocking potentially
Lokon Pharma has announced a collaboration with Affibody to combine oncolytic viruses with Affibody molecules. “Lokon’s oncolytic adenovirus platform encodes human immunostimulatory genes to induce anti-tumor immunity in cancer patients.
Orion Corporation and CuraTeQ Biologics have expanded their biosimilar distribution agreement to the Baltic countries. The original marketing and distribution agreement signed in 2020 covered the Nordics, Austria, Hungary and
Rafael Natanek was raised and educated in Sweden. He spent 15 years working out of the UK, serving life science companies across Europe and the U.S. Today he is located
Valo Therapeutics has announced the acquisition of intellectual property rights from the University of Helsinki for the technology which utilizes pre-existing immunity (PEI) against pathogens to enhance the therapeutic efficacy
Alexion, AstraZeneca’s Rare Disease group, has entered into an exclusive global collaboration and licence agreement with Neurimmune for NI006, an investigational human monoclonal antibody currently in Phase Ib development for
Immunicum has announced to transfer its patent rights for modified adenovirus (patent US 9,017,672 B2) to Elicera Therapeutics. The patent is currently out-licensed to Elicera and covers a modified adenovirus
The COVID-19 pandemic
The last manufacturing steps of the company’s Evusheld (previously AZD7442) will take place in Södertälje, Sweden. Packaging and release of the potential new drug, a combination of long-acting antibodies that
Nykode Therapeutics has announced that the first subject has been dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate in its VB-D-01 Phase 1/2 trial. The T cell specific
An international metastudy led by researchers at Karolinska Institutet has identified a specific gene variant that protects against severe COVID-19 infection. The researchers managed to pinpoint the variant by studying
The European Commission (EC) has granted Novavax conditional marketing authorization (CMA) for Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years
The Committee for Medicinal Products for Human Use of the EMA has adopted a positive opinion of Kineret for the treatment of COVID-19 in adult patients with pneumonia requiring supplemental
Profile Abroad
An adventurous spirit rooted in a Viking heritage and her parents’ as an example helped spur Gitte Pedersen to move from her native Denmark to the U.S. 20 years ago,
Drug and device development
Spago Nanomedical has completed the studies in the regulatory preclinical program with its leading candidate drug Tumorad (SN201). It displays a good safety margin to clinically relevant doses, states the
Interim results from the second dose group in the company’s ongoing clinical phase I study SPAGOPIX-01 show that SpagoPix (SN132D) is well tolerated and provides clear contrast enhancement in MRI
Data from the phase 3 OCEAN study, evaluating the efficacy and safety of melflufen plus dexamethasone versus pomalidomide plus dexamethasone in lenalidomide refractory patients with relapsed refractory multiple myeloma that
Ilya Pharma is planning to submit an Investigational New Drug Application (IND) for a Phase 1/2a safety and dose finding clinical study of ILP100-Oral, the company’s investigational immunotherapy being developed
Sigrid Therapeutics has announced that the results from their Proof-of-Concept STAR study have been published in Nanomedicine. Oral administration of the company’s lead product SiPore15 to subjects with prediabetes or
Profile
Malin Parkler, CEO of Pfizer Sweden, is driven by curiosity and a passion to build knowledge and evolve the life science industry – with the ultimate goal to yield real
In a new job
Finding and securing talent is critical for the growth of the life sciences sector, this is widely accepted. The ever-present questions are how to keep up with the demand and
Industrifonden has announced that Peter Wolpert has been appointed its new CEO. Wolpert has extensive experience developing and taking life science and tech companies to market, states Industrifonden. He will
Lundbeck has announced that Jacob Tolstrup, Executive Vice President for Commercial Operations, is promoted to Chief Commercial Officer, effective 1 January 2022. Jacob will be responsible for sales and marketing
Careers
Business development in a clinical stage vaccine company is constantly changing, intellectually challenging and meaningful job that pushes developments in society. Caspar Foghsgaard is Director of Business Development at the
Read the latest issue of our magazine!
No 04 2021 // Real-World Evidence has taken a leap forward during the pandemic. Read more about the potential of RWE in drug development, and how we can better enable Nordic health data to be transformative and a frontrunner in this field.
In this issue we have also chosen to turn the spotlight on four successful Nordic profiles abroad. They all provide valuable insights from the global life science industry and give perspectives on the Nordic one.
Last but not least, a very hot topic in the spotlight in this issue is the quest to find and secure talent. We take a closer look on how to keep up with the demand and with whom the responsibility rests to solve the skills supply challenge.
Venture Capital
Nordic Life Science asked Fredrik Dahl, co-founder at Colibri Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges Nordic life science
Nordic Life Science asked Claus Andersson, General Manager at Sunstone Life Science Venture, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
Nordic Life Science asked Inka Mero, Founder and Managing Partner at Voima Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
“Start by asking what the problem is that you are trying to solve and develop the technology, team, and plan to solve that problem – not what you can do with the technology.” – Fredrik Dahl, Colibri Ventures
Upcoming events
This event will be arranged as an in-person event in San Francisco January 10-12 and a virtual event January 17-19. The 2022 program will feature insights from top investors and
The J.P. Morgan 40th Annual Healthcare Conference will take place at the Westin St. Francis Hotel in San Francisco, CA. USA. This annual conference brings together industry leaders, emerging companies,
Cancer Crosslinks, arranged in person in Oslo and as a digital event, promotes interactions between researchers and clinicians, and encourages translational and clinical research. This event has become a leading
This springtime hybrid event will be delivered in-person in Basel, March 28-30, and digitally, 4-6 April. BIO-Europe Spring, arranged annually in different cities within Europe, is an international forum to
The latest research news from the Nordic region
Science Article
Foundations behind Medicon Village has decided to award almost 25 million SEK to nine research projects in Malmö and Lund. Mats Paulsson’s foundation for research, innovation and community building has
A new invention to measure the size of protein aggregates (proteins that clump together) can determine very precisely whether a person has systemic lupus erythematosus (SLE) or not and the
This global prize aims to reward scientists at an early stage of their careers. The Science & SciLifeLab Prize for Young Scientists was established in 2013. Science, the American Association
Researchers from Karolinska Institutet and the SciLifeLab Chemical Biology Consortium Sweden (CBCS) have identified a chemical compound, CBK77, that has the potential to inhibit protein recycling in cancer cells, subsequently
Researchers at Karolinska Institutet, Umeå University, and the University of Bonn have identified a new group of molecules that have an antibacterial effect against many antibiotic-resistant bacteria. Since the properties
The human brain, consisting of approximately 86 billion neurons connected by around 100 trillion synapses (Herculano-Houzel, 2009), is in many aspects still a mystery. Many questions remain unsolved, from understanding
Nordic Life Science
The latest clinical trials
Interim results from the second dose group in the company’s ongoing clinical phase I study SPAGOPIX-01 show that SpagoPix (SN132D) is well tolerated and provides clear contrast enhancement in MRI
Data from the phase 3 OCEAN study, evaluating the efficacy and safety of melflufen plus dexamethasone versus pomalidomide plus dexamethasone in lenalidomide refractory patients with relapsed refractory multiple myeloma that
Ilya Pharma is planning to submit an Investigational New Drug Application (IND) for a Phase 1/2a safety and dose finding clinical study of ILP100-Oral, the company’s investigational immunotherapy being developed
Sigrid Therapeutics has announced that the results from their Proof-of-Concept STAR study have been published in Nanomedicine. Oral administration of the company’s lead product SiPore15 to subjects with prediabetes or
Updated results from the ASCEND Phase III trial showed AstraZeneca’s Calquence (acalabrutinib) maintained a statistically significant progression-free survival (PFS) benefit at three years compared to investigator’s choice of rituximab combined
Affibody, ACELYRIN, and Inmagene Biopharmaceuticals, have announced that a 16-week, global, Phase 2 clinical trial of izokibep in patients with psoriatic arthritis (PsA) met its primary endpoint in a pre-specified
Ultimovacs has announced that the first patient has been enrolled in the DOVACC (Durvalumab Olaparib VACCine) study, a randomized Phase II clinical trial assessing the impact of the Company’s telomerase
Elypta announces the enrollment of the first patient in the newly initiated AURORAX-0093A (AUR93A) study. AUR93A is intended to explore Elypta’s metabolism-based liquid biopsy platform for the prognosis of muscle-invasive
The last manufacturing steps of the company’s Evusheld (previously AZD7442) will take place in Södertälje, Sweden. Packaging and release of the potential new drug, a combination of long-acting antibodies that
Sign up to our newsletter